Contact Us

Phone Number : +86 13989889852

WhatsApp : +008613989889852

AllTest COVID-19 Antigen Test Kit is Approved for Marketing in China

March 30, 2022



Hangzhou AllTest Biotech Co.,Ltd , a company in Qiantang District, was approved to market in China, the novel coronavirus (2019-nCoV) antigen test kit (latex method), which is used to detect SARS-CoV-2 that causes COVID-19. It is used to detect novel coronavirus N and S protein antigens in nasopharyngeal swab samples from suspected people. This product is the third approved product of COVID-19 antigen test kit in Zhejiang Province.


As a complementary method for epidemic prevention and control, the Antigen Test has the advantages of convenient and self-testable. During the epidemic, AllTest has developed a series of rapid test kits like: COVID-19 IgG/IgM Antibody Test Kit, COVID-19 Antigen Rapid Test (nasal swab/ oral fluid) and other COVID-19 rapid test reagents. Moreover, these products has obtained CE1434 certification of EU, TGA certification of Australia, etc. The AllTest brand is globally recognized and has helped control the spread of COVID-19 in more than 150 countries and regions worldwide, and registered successfully in Hong Kong in February this year.


As a bio-pharmaceutical high-tech enterprise specializing in the R&D, production and sales of in vitro diagnostic (IVD) reagents, AllTest mainly produce rapid test reagents, including five series of drug of abuse rapid test, infectious disease rapid test, women's health rapid test, tumor markers rapid test and cardiac marker rapid test.


“Strong technology development and innovation capability is a major feature of AllTest Bio., and we will continue to inject new energy into the industry and actively participate in the development and progress of the bio-pharmaceutical industry.” The manager of AllTest said that.


Hangzhou Pharmaceutical Port, where AllTest is located, is the core area for the development of bio-pharmaceutical industry in Hangzhou and Zhejiang Province. 7 of the World's Top 10 pharmaceutical companies such as Abbott and Johnson & Johnson have settled in there, 19 listed and key companies to be listed, 29 high-powered platforms such as the Institute of Medicine of the Chinese Academy of Sciences, the Institute of Intelligent and Innovative Drugs of Zhejiang University and the public service platform for bio-pharmaceutical innovation of the Provincial Drug Administration have been landed, and a new model of "chain + cluster" has been built. "In 2021, 20 new innovative drugs will start clinical trials, 14 generic drugs will start bio-equivalence trials, 208 medical devices will be approved, and the revenue of bio-pharmaceutical enterprises will reach 45 billion yuan, with an average annual increase of more than 15% in the past three years, maintaining a good development trend.




It is worth mentioning that on the evening of March 16, Qiantang District Market Supervision Bureau was informed that AllTest's COVID-19 Antigen Test kit entered the national emergency approval channel, the provincial Drug Inspection Center expert group carried out overnight product registration system verification, as well as the municipal leadership attaches great importance to the coordination of inspection services led by the team overnight, and finally AllTest successfully passed the registration verification.